In the present study, we therefore investigated the effects of CDC25 inhibition on AML cell viability, proliferation, and constitutive cytokine release; however, CDC25 inhibition was also combined with the mTOR complex 1 (mTORC1)-targeting rapamycin and the PI3K-targeting GDC0941. This evidence concerns the gene CDC25C and acute myeloid leukemia.